Search Medical Condition
Please enter condition
Please choose location

Morfelden-Walldorf, Germany Clinical Trials

A listing of Morfelden-Walldorf, Germany clinical trials actively recruiting patients volunteers.

RESULTS

Found (152) clinical trials

The European Paediatric Network for Haemophilia Management ( PedNet Registry)

Design: Prospective observational cohort Population Patients with haemophilia A and B with FVIII/IX levels of <1 to 25% born between 1-1-2000 and 1-1-2020. Intervention No intervention; only documentation of patient characteristics and parameters of routine patient care and outcome Main outcome parameters: Outcome: clinically relevant inhibitor development, bleeding pattern and ...

Phase N/A

0.0 miles

Learn More »

A Survey on the Success of Inhibitor Elimination Using Individualized Concentrate Selection and Controlled ITI

As a result of many technological advances in the last two decades, current factor VIII (FVIII) concentrates (both plasma-derived and recombinant products) are considered very safe in terms of pathogen safety. The development of inhibitors against FVIII or factor IX (FIX) is considered as a major complication during replacement therapy ...

Phase N/A

0.0 miles

Learn More »

Safety and Efficacy of Nonacog Beta Pegol (N9-GP) in Previously Untreated Patients With Haemophilia B

This trial is conducted globally. The aim of the trial is to investigate the safety and efficacy of nonacog beta pegol (N9-GP) in previously untreated patients with Haemophilia B.

Phase

0.0 miles

Learn More »

A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors

This is a phase IIIb, single arm, open-label, multi-center study to evaluate the safety and tolerability of emicizumab in participants with congenital hemophilia A who have documented inhibitors against Factor VIII (FVIII) at enrollment. Approximately 200 participants, aged 12 or older, will be enrolled in this study and are expected ...

Phase

0.0 miles

Learn More »

Firazyr Patient Registry Protocol (Icatibant Outcome Survey - IOS)

The Firazyr Patient Registry is a multicenter, prospective, observational study for patients treated with Firazyr in countries where it is currently approved. The entry of patients into the Firazyr Registry is at the discretion of the physician and the patient and is not a pre-requisite for prescribing Firazyr.

Phase N/A

0.0 miles

Learn More »

Praegnant Breast Cancer

Among patients with breast cancer the subgroup of patients with metastases are considered the group of patients with the worst prognosis. Not only with regard to therapy decisions but also with regard to quality assured healthcare and health economics this entity of patients remains a challenge. Recently, novel advances in ...

Phase N/A

4.53 miles

Learn More »

Comparison of Pre- and Post-discharge Initiation of LCZ696 Therapy in HFrEF Patients After an Acute Decompensation Event

To explore two modalities of treatment initiation (Pre-discharge, and Post-discharge) with LCZ696 in HFrEF patients following stabilization after an ADHF episode.

Phase

4.53 miles

Learn More »

Registrational Study With Omecamtiv Mecarbil/AMG 423 to Treat Chronic Heart Failure With Reduced Ejection Fraction

The purpose of this study is to determine if treatment with omecamtiv mecarbil/AMG 423 when added to standard of care is well tolerated and superior to placebo in reducing the risk of cardiovascular death or heart failure events in subjects with chronic HFrEF.

Phase

4.53 miles

Learn More »

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

This is a randomized (the study medication is assigned by chance), double-blind (neither physician nor participant knows the identity of the assigned treatment), parallel group (each participant group receives different treatments simultaneously), event driven (the study duration is determined by the time taken for a specific number of events to ...

Phase

4.53 miles

Learn More »

EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)

The aim of the study is to evaluate efficacy and safety of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with preserved ejection fraction

Phase

4.53 miles

Learn More »